Roswell Park Comprehensive Cancer Center

New Capabilities

As of May 2026: Presenting GLP-1 and breast cancer data at ASCO 2026 on June 1 that challenges the Cleveland Clinic's positive findings

A study of more than 12,000 patients found that those taking GLP-1 weight-loss drugs were 38% to 50% less likely to progress to stage IV cancer in four obesity-linked cancers. Cleveland Clinic led the study. Researchers compared GLP-1 users — on drugs like Ozempic, Wegovy, and Mounjaro — against patients taking older diabetes pills.

Updated May 24